Antidepressant Use during Pregnancy and Serotonin Transporter Genotype (SLC6A4) Affect Newborn Serum Reelin Levels

UBC Faculty Research and Publications

Antidepressant Use during Pregnancy and Serotonin Transporter Genotype (SLC6A4) Affect Newborn Serum Reelin Levels Brummelte, Susanne; Galea, Liisa A. M.; Devlin, Angela Marie; Oberlander, Tim F.

Abstract

This study was undertaken to determine whether altered early serotonin signaling either via gestational serotonin reuptake inhibitor (SRI) exposure or genetic variations in the serotonin transporter promoter region (SLC6A4) alters levels of reelin, an important glycoprotein in neurodevelopment, in mothers and their neonates. Serum reelin protein expression was quantified by immunoblot from maternal and neonatal blood collected at delivery from women taking either an SRI during gestation or controls. SRI-exposed mothers had higher levels of one reelin fragment, while SRI-exposed neonates had lower total reelin levels, particularly in females and reelin levels differed with SLC6A4 genotype. Lower neonatal reelin levels predicted less time spent sleeping and more irritability during neonatal behavioral assessment on day 6 of life. Our results suggest that prenatal SRI exposure and the SLC6A4 genotype influences reelin protein expression in both the mother and newborn and that this may be reflected in neonatal behavior.

Item Metadata

Title	Antidepressant Use during Pregnancy and Serotonin Transporter Genotype (SLC6A4) Affect Newborn Serum Reelin Levels
Alternate Title	Reelin changes after antenatal antidepressants
Creator	Brummelte, Susanne; Galea, Liisa A. M.; Devlin, Angela Marie; Oberlander, Tim F.
Contributor	Djavad Mowafaghian Centre for Brain Health; Child and Family Research Institute; Children's Hospital (Vancouver, B.C.). Metabolic Nutrition
Date Issued	2013
Description	This study was undertaken to determine whether altered early serotonin signaling either via gestational serotonin reuptake inhibitor (SRI) exposure or genetic variations in the serotonin transporter promoter region (SLC6A4) alters levels of reelin, an important glycoprotein in neurodevelopment, in mothers and their neonates. Serum reelin protein expression was quantified by immunoblot from maternal and neonatal blood collected at delivery from women taking either an SRI during gestation or controls. SRI-exposed mothers had higher levels of one reelin fragment, while SRI-exposed neonates had lower total reelin levels, particularly in females and reelin levels differed with SLC6A4 genotype. Lower neonatal reelin levels predicted less time spent sleeping and more irritability during neonatal behavioral assessment on day 6 of life. Our results suggest that prenatal SRI exposure and the SLC6A4 genotype influences reelin protein expression in both the mother and newborn and that this may be reflected in neonatal behavior.
Subject	Antenatal depression; Selective serotonin reuptake inhibitors (SSRI); Serotonin norepinephrine reuptake inhibitor (SNRI); Development; Gestation; Infant; Mood; Neurobehavioral assessment of the preterm infant (NAPI)
Genre	Article; Postprint
Type	Text
Language	eng
Date Available	2019-05-22
Provider	Vancouver : University of British Columbia Library
Rights	Attribution-NonCommercial-NoDerivatives 4.0 International
DOI	10.14288/1.0378931
URI	http://hdl.handle.net/2429/70241
Affiliation	Arts, Faculty of; Medicine, Faculty of; Non UBC; Pediatrics, Department of; Psychology, Department of
Citation	Brummelte, S., Galea, L. A. M., Devlin, A. M., & Oberlander, T. F. (2013). Antidepressant use during pregnancy and serotonin transporter genotype (SLC6A4) affect newborn serum reelin levels. Developmental Psychobiology, 55(5), 518-529.
Publisher DOI	10.1002/dev.21056
Peer Review Status	Reviewed
Scholarly Level	Faculty; Researcher
Rights URI	http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository	DSpace

Open Collections

UBC Faculty Research and Publications